Apellis Pharmaceuticals, Inc. (APLS) 當前追蹤本益比 (P/E) 為 229.3, 前瞻本益比為 33.8. 追蹤盈利收益率為 0.44%, 前瞻盈利收益率 2.96%. PEG 0.06 (Peter Lynch 低估標準 ≤1.0). 葛拉漢數為 $3.43.
本頁證實的標準:
SharesGrow 綜合評分： 48/100 其中 1/7 項標準通過。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -9.4 | 0.22 | 10.67 | 0.00 | - |
| 2017 | -14.6 | 21.84 | 4.99 | 0.00 | - |
| 2018 | -5.6 | -0.10 | 4.46 | 0.00 | - |
| 2019 | -6.3 | -0.06 | 55.67 | 0.00 | - |
| 2020 | -12.5 | 1.59 | 21.02 | 17.15 | - |
| 2021 | -5.3 | -0.06 | 20.09 | 59.96 | - |
| 2022 | -8.4 | 0.28 | 32.30 | 72.75 | - |
| 2023 | -13.4 | 0.49 | 36.52 | 17.91 | - |
| 2024 | -20.0 | 0.31 | 17.30 | 5.06 | - |
| 2025 | 141.4 | -1.27 | 8.55 | 3.15 | - |
| Year | EPS（稀釋） | 營收 | 淨利潤 | 淨利潤率 |
|---|---|---|---|---|
| 2016 | $-1.50 | $0.00 | $-27.13M | - |
| 2017 | $-3.68 | $0.00 | $-51.01M | - |
| 2018 | $-2.34 | $0.00 | $-127.5M | - |
| 2019 | $-4.98 | $0.00 | $-309.82M | - |
| 2020 | $-4.59 | $250.65M | $-344.87M | -137.6% |
| 2021 | $-8.84 | $66.56M | $-746.35M | -1121.3% |
| 2022 | $-6.15 | $75.42M | $-652.17M | -864.7% |
| 2023 | $-4.45 | $396.59M | $-528.63M | -133.3% |
| 2024 | $-1.60 | $781.37M | $-197.88M | -25.3% |
| 2025 | $0.18 | $1B | $22.39M | 2.2% |
| Year | EPS（平均） | EPS 範圍 | 營收（平均） | 營收範圍 | 分析師人數 |
|---|---|---|---|---|---|
| 2026 | $-1.12 | $-1.95 – $-0.68 | $861.54M | $813.33M – $928.62M | 15 |
| 2027 | $-0.20 | $-0.76 – $0.11 | $1.02B | $893.21M – $1.16B | 14 |
| 2028 | $1.18 | $-0.92 – $7.82 | $1.26B | $1.26B – $1.26B | 17 |
| 2029 | $1.50 | $1.30 – $1.73 | $1.37B | $1.22B – $1.53B | 13 |
| 2030 | $2.48 | $2.14 – $2.86 | $1.54B | $1.37B – $1.72B | 7 |
